FDA Clears Skyrizi Injection Regimen to Start Crohn’s Care
FDA approval gives adults with Crohn’s disease a new Skyrizi induction route, putting injection delivery and practical treatment access in focus.

The U.S. FDA approved a subcutaneous induction regimen of AbbVie’s Skyrizi for adults with moderately to severely active Crohn’s disease, supported by the pivotal Phase 3 AFFIRM study.
The U.S. FDA has approved a subcutaneous induction regimen of AbbVie’s Skyrizi for adults with moderately to severely active Crohn’s disease, expanding how eligible patients can begin treatment. The new regimen uses injections under the skin and an on-body injector, bringing that delivery approach into the opening stage of care.
The decision concerns treatment administration, not a newly approved medicine or a broader patient population. Its practical importance lies in making the way patients start Skyrizi more consistent with an injection-based treatment course. Whether that translates into easier access or a better experience will depend on prescribing instructions, coverage and the support patients receive.
AbbVie announced the approval and identified the pivotal Phase 3 AFFIRM study as supporting evidence, according to PR Newswire Biotech. The announcement describes the subcutaneous approach as supporting early symptom control and endoscopic control, which concerns disease assessed by looking inside the digestive tract.
The approval changes the opening stage of treatment
Induction is the initial phase of a treatment regimen, intended to bring active disease under control. Maintenance is the continuing phase intended to sustain that response. A change to induction can therefore matter even when the medicine itself remains the same: the logistics of starting treatment are part of the overall burden of care.
Subcutaneous administration means delivering medicine beneath the skin. An on-body injector is a device used to administer that treatment. The approval brings this route into Skyrizi induction for the specified adult Crohn’s disease population, rather than establishing a general authorization for every use of the medicine.
For patients and clinicians, the immediate distinction is between choosing a drug and choosing an approved way to administer it. A patient’s disease activity, medical history and ability to manage a device remain relevant to that discussion. Regulatory approval makes the regimen an available option; it does not establish that every eligible patient should switch to it.
The device also should not be treated as a substitute for clinical supervision. Instructions on preparation, administration and follow-up still matter. The exact dose, schedule and conditions for using the new induction regimen should come from the approved prescribing information and the treating clinician, rather than assumptions based on the delivery route.
AFFIRM supports the decision, but the endpoints matter
The pivotal Phase 3 AFFIRM study is the central clinical evidence identified for the new regimen. The available announcement says subcutaneous Skyrizi achieved superior clinical results, but does not identify the comparator or the specific endpoint behind that statement. That limits how precisely the finding can be interpreted.
In a clinical trial, an endpoint is the defined outcome used to judge a treatment. A superiority finding applies to the particular comparison and outcome tested. Without those details, it would be inappropriate to describe the regimen as superior to another named medicine, to every other administration route or across all measures of Crohn’s disease control.
Symptomatic and endoscopic outcomes also answer different questions. Symptoms concern how a patient feels and functions. Endoscopic assessment examines disease inside the digestive tract. Both can be important, but a broad statement about clinical benefit does not establish the size, timing or durability of an effect on either measure.
Both can be important, but a broad statement about clinical benefit does not establish the size, timing or durability of an effect on either measure.
The details to examine next are therefore the trial’s defined outcomes, comparison group, treatment schedule and safety findings. Those would help clinicians understand which benefits were demonstrated and how closely the study population resembles a particular patient. No numerical efficacy result or detailed safety comparison can be established from the supplied announcement.
Patient convenience depends on more than the device
An injection-based induction option can change the practical conversation around starting treatment. Patients may consider how administration fits with work, transportation, caregiving and other medical appointments. Clinicians may consider training needs and whether a patient has the support required to follow the regimen correctly.
Those are potential advantages to evaluate, not measured benefits established by this approval announcement. The new route alone does not prove fewer appointments, lower personal costs or faster access. Nor does it establish that treatment can begin immediately for every eligible patient.
Insurance coverage and dispensing arrangements remain separate from FDA authorization. Approval addresses whether a regimen may be used for the specified indication; coverage determines how a particular patient obtains it and what financial conditions apply. A convenient administration method can still encounter practical barriers before treatment begins.
Patients already receiving Skyrizi should also distinguish the new induction authorization from their existing treatment instructions. An approval affecting the start of care is not, by itself, a direction to alter an ongoing regimen. Any change should be discussed with the prescribing team, with attention to the patient’s current treatment stage.
AbbVie gains another treatment option, not a sales forecast
For AbbVie, the regulatory decision adds flexibility to an existing medicine’s use in Crohn’s disease. Administration can influence treatment selection alongside efficacy, safety and access. A more suitable delivery option may help address a practical concern that would otherwise complicate the decision to begin therapy.
That commercial opportunity remains distinct from demonstrated financial impact. The approval does not supply a revenue forecast, a pricing change or evidence of additional prescriptions. It also does not establish that clinicians will choose the new regimen over other available approaches. Those outcomes depend on adoption after approval.
AbbVie shares, identified in the supplied market data as ABBV, were up 0.18% at the last trade recorded at 20:00 GMT on October 23, 2026. That modest intraday move does not establish how much investors attributed to the regulatory decision, and it should not be read as a measure of the regimen’s eventual commercial value.
The next test is practical implementation: clear prescribing guidance, clinician familiarity with the induction option, patient training and workable coverage. The FDA decision establishes a new route for starting Skyrizi in the approved adult population. Its value in everyday care will depend on how well that option fits individual patients’ medical and logistical needs.
Key facts
- FDA decision: Subcutaneous Skyrizi induction approved for adults with moderately to severely active Crohn’s disease.
- Administration: The new induction route uses subcutaneous administration and an on-body injector.
- Supporting study: Pivotal Phase 3 AFFIRM; the supplied announcement does not specify the comparator or endpoint behind the superiority statement.
- Market snapshot: ABBV: 285.69, currency and exchange unspecified in supplied data; up 0.18% as of October 23, 2026, at 20:00 GMT.
Frequently asked questions
What did the FDA approve for Skyrizi?
The U.S. FDA approved a subcutaneous induction regimen of Skyrizi for adults with moderately to severely active Crohn’s disease. The decision concerns how treatment can begin, using administration beneath the skin and an on-body injector. It does not establish a new medicine or expand the stated eligible population.
What does induction mean in Crohn’s disease treatment?
Induction is the opening phase of treatment, intended to bring active disease under control. Maintenance is the continuing phase intended to sustain the response. The Skyrizi approval adds a subcutaneous option for induction, making the delivery method at the start of care an additional consideration for patients and clinicians.
What did the AFFIRM study demonstrate?
The supplied announcement identifies AFFIRM as a pivotal Phase 3 study and says subcutaneous Skyrizi achieved superior clinical results. It does not specify the comparator, endpoint or numerical effect. Consequently, the available information cannot support a claim that the regimen outperformed a particular named medicine or every alternative administration approach.
Does the new regimen mean patients can change treatment themselves?
No. Approval of a new induction route is not an instruction for patients to alter their current treatment. The dose, schedule, device instructions and appropriate setting should be confirmed through approved prescribing information and the treating clinician. Patients already receiving Skyrizi should discuss whether the new authorization is relevant to their treatment stage.
Does subcutaneous induction guarantee lower costs or fewer appointments?
The approval announcement does not establish lower patient costs, fewer appointments or faster access. An injection-based option may change treatment logistics, but its practical benefits depend on prescribing requirements, training, coverage and dispensing arrangements. FDA authorization and an insurer’s coverage decision address different questions and should not be treated as interchangeable.
What does the approval mean for AbbVie’s business?
The decision gives AbbVie another approved way to initiate Skyrizi treatment in the specified Crohn’s disease population. That may help address administration preferences, but the announcement provides no revenue forecast, pricing change or prescription-growth result. Commercial impact will depend on clinician adoption, patient suitability and access to the new regimen.
Sources
- U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease — PR Newswire Biotech
Photo: kumarsu6745_ · Pixabay Content License — source


